Immunic to host multiple sclerosis r&d day and participate in scientific and investor conferences in september

New york , aug. 28, 2024 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will host a multiple sclerosis (ms) research and development (r&d) day and participate in the following scientific and investor conferences in september: september 10: immunic's ms r&d day. management of immunic, including daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking